Plain-English translation of NCT06802835 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a combination of three medications—an , a PD-1 inhibitor, and chemotherapy—given together to treat nasopharyngeal cancer that has returned or spread to other parts of the body. Researchers want to see if using all three drugs at once helps people live longer and controls their cancer better than previous approaches. The trial will enroll about 148 patients across multiple hospitals.
Nasopharyngeal cancer that comes back after initial treatment is very difficult to manage, and current options don't work well for everyone. This trial aims to find out whether combining three different types of cancer-fighting drugs might be more effective than treating with just one or two.
You likely qualify if…
You likely don't qualify if…
You would receive the three-drug combination through infusions and possibly pills, likely given on a regular schedule (such as every few weeks) at the hospital. Throughout the trial, you would have regular blood tests, imaging scans to measure your tumor, and visits to check how you are tolerating the medications and managing any side effects. The study aims to track your response to treatment and overall health over several months to a year.
AI-generated summary from trial data · Jul 6, 2026 · Not medical advice
China